Search

Your search keyword '"Dahlrot, R. H."' showing total 25 results
Start Over Author "Dahlrot, R. H."
25 results on '"Dahlrot, R. H."'

5. Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

Author

Mohammad, H., Madsen, K., Graumann, O., Loya, A. C., Jensen, N., Dahlrot, R. H., Mohammad, H., Madsen, K., Graumann, O., Loya, A. C., Jensen, N., and Dahlrot, R. H.

Abstract

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

Published
2022

9. Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Author

Petersen, J. K., primary, Boldt, H. B., additional, Sørensen, M. D., additional, Blach, S., additional, Dahlrot, R. H., additional, Hansen, S., additional, Burton, M., additional, Thomassen, M., additional, Kruse, T., additional, Poulsen, F. R., additional, Andreasen, L., additional, Hager, H., additional, Ulhøi, B. P., additional, Lukacova, S., additional, Reifenberger, G., additional, and Kristensen, B. W., additional

Published
2020
Full Text
View/download PDF

11. Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics.

Author

Petersen, J. K., Boldt, H. B., Sørensen, M. D., Blach, S., Dahlrot, R. H., Hansen, S., Burton, M., Thomassen, M., Kruse, T., Poulsen, F. R., Andreasen, L., Hager, H., Ulhøi, B. P., Lukacova, S., Reifenberger, G., and Kristensen, B. W.

Subjects
NUCLEOTIDE sequencing, ASTROCYTOMAS, GLIOMAS, ISOCITRATE dehydrogenase, CENTRAL nervous system, ADULTS
Abstract

Aims: We aimed to reclassify a population‐based cohort of 529 adult glioma patients to evaluate the prognostic impact of the 2016 World Health Organization (WHO) central nervous system tumour classification. Moreover, we evaluated the feasibility of gene panel next‐generation sequencing (NGS) in daily diagnostics of 225 prospective glioma patients. Methods: The retrospective cohort was reclassified according to WHO 2016 criteria by immunohistochemistry for IDH‐R132H, fluorescence in situ hybridization for 1p/19q‐codeletion and gene panel NGS. All tumours of the prospective cohort were subjected to NGS analysis up‐front. Results: The entire population‐based cohort was successfully reclassified according to WHO 2016 criteria. NGS results were obtained for 98% of the prospective patients. Survival analyses in the population‐based cohort confirmed three major prognostic subgroups, that is, isocitrate dehydrogenase (IDH)‐mutant and 1p/19q‐codeleted oligodendrogliomas, IDH‐mutant astrocytomas and IDH‐wildtype glioblastomas. The distinction between WHO grade II and III was prognostic in patients with IDH‐mutant astrocytoma. The survival of patients with IDH‐wildtype diffuse astrocytomas carrying TERT promoter mutation and/or EGFR amplification overlapped with the poor survival of IDH‐wildtype glioblastoma patients. Conclusions: Gene panel NGS proved feasible in daily diagnostics. In addition, our study confirms the prognostic role of glioma classification according to WHO 2016 in a large population‐based cohort. Molecular features of glioblastoma in IDH‐wildtype diffuse glioma were linked to poor survival corresponding to IDH‐wildtype glioblastoma patients. The distinction between WHO grade II and III retained prognostic significance in patients with IDH‐mutant diffuse astrocytic gliomas. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis

Author

Dahlrot, R H, Dowsett, J, Fosmark, S, Malmström, A, Henriksson, R, Boldt, H, de Stricker, K, Sørensen, M D, Poulsen, H S, Lysiak, M, Söderkvist, P, Rosell, J, Hansen, S, Kristensen, B W, Dahlrot, R H, Dowsett, J, Fosmark, S, Malmström, A, Henriksson, R, Boldt, H, de Stricker, K, Sørensen, M D, Poulsen, H S, Lysiak, M, Söderkvist, P, Rosell, J, Hansen, S, and Kristensen, B W

Abstract

AIMS: It is important to predict response to treatment with temozolomide (TMZ) in glioblastoma (GBM) patients. Both MGMT protein expression and MGMT promoter methylation status have been reported to predict the response to TMZ. We investigated the prognostic value of quantified MGMT protein levels in tumour cells and the prognostic importance of combining information of MGMT protein level and MGMT promoter methylation status.METHODS: MGMT protein expression was quantified in tumour cells in 171 GBMs from the population-based Region of Southern Denmark (RSD)-cohort using a double immunofluorescence approach. Pyrosequencing was performed in 157 patients. For validation we used GBM-patients from a Nordic Study (NS) investigating the effect of radiotherapy and different TMZ schedules.RESULTS: When divided at the median, patients with low expression of MGMT protein (AF-low) had the best prognosis (HR = 1.5, P = 0.01). Similar results were observed in the subgroup of patients receiving the Stupp regimen (HR = 2.0, P = 0.001). In the NS-cohort a trend towards superior survival (HR = 1.6, P = 0.08) was seen in patients with AF-low. Including MGMT promoter methylation status, we found for both cohorts that patients with methylated MGMT promoter and AF-low had the best outcome; median OS 23.1 and 20.0 months, respectively.CONCLUSION: Our data indicate that MGMT protein expression in tumour cells has an independent prognostic significance. Exclusion of nontumour cells contributed to a more exact analysis of tumour-specific MGMT protein expression. This should be incorporated in future studies evaluating MGMT status before potential integration into clinical practice.

Published
2018

16. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis

Author

Dahlrot, R. H., primary, Dowsett, J., additional, Fosmark, S., additional, Malmström, A., additional, Henriksson, R., additional, Boldt, H., additional, de Stricker, K., additional, Sørensen, M. D., additional, Poulsen, H. S., additional, Lysiak, M., additional, Söderkvist, P., additional, Rosell, J., additional, Hansen, S., additional, and Kristensen, B. W., additional

Published
2017
Full Text
View/download PDF

20. PATHOLOGY

Author

Adachi, J.-i., primary, Totake, K., additional, Shirahata, M., additional, Mishima, K., additional, Suzuki, T., additional, Yanagisawa, T., additional, Fukuoka, K., additional, Nishikawa, R., additional, Arimappamagan, A., additional, Manoj, N., additional, Mahadevan, A., additional, Bhat, D., additional, Arvinda, H., additional, Indiradevi, B., additional, Somanna, S., additional, Chandramouli, B., additional, Petterson, S. A., additional, Hermansen, S. K., additional, Dahlrot, R. H., additional, Hansen, S., additional, Kristensen, B. W., additional, Carvalho, F., additional, Jalali, S., additional, Singh, S., additional, Croul, S., additional, Aldape, K., additional, Zadeh, G., additional, Choi, J., additional, Park, S.-H., additional, Khang, S. K., additional, Suh, Y.-L., additional, Kim, S. P., additional, Lee, Y. S., additional, Kim, S. H., additional, Coberly, S., additional, Samayoa, K., additional, Liu, Y., additional, Kiaei, P., additional, Hill, J., additional, Patterson, S., additional, Damore, M., additional, Dahiya, S., additional, Emnett, R., additional, Phillips, J., additional, Haydon, D., additional, Leonard, J., additional, Perry, A., additional, Gutmann, D., additional, Epari, S., additional, Ahmed, S., additional, Gurav, M., additional, Raikar, S., additional, Moiyadi, A., additional, Shetty, P., additional, Gupta, T., additional, Jalali, R., additional, Georges, J., additional, Zehri, A., additional, Carlson, E., additional, Martirosyan, N., additional, Elhadi, A., additional, Nichols, J., additional, Ighaffari, L., additional, Eschbacher, J., additional, Feuerstein, B., additional, Anderson, T., additional, Preul, M., additional, Jensen, K., additional, Nakaji, P., additional, Girardi, H., additional, Monville, F., additional, Carpentier, S., additional, Giry, M., additional, Voss, J., additional, Jenkins, R., additional, Boisselier, B., additional, Frayssinet, V., additional, Poggionovo, C., additional, Catteau, A., additional, Mokhtari, K., additional, Sanson, M., additional, Peyro-Saint-Paul, H., additional, Giannini, C., additional, Hide, T., additional, Nakamura, H., additional, Makino, K., additional, Yano, S., additional, Anai, S., additional, Shinojima, N., additional, Kuroda, J.-i., additional, Takezaki, T., additional, Kuratsu, J.-i., additional, Higuchi, F., additional, Matsuda, H., additional, Iwata, K., additional, Ueki, K., additional, Kim, P., additional, Kong, J., additional, Cooper, L., additional, Wang, F., additional, Gao, J., additional, Teodoro, G., additional, Scarpace, L., additional, Mikkelsen, T., additional, Schniederjan, M., additional, Moreno, C., additional, Saltz, J., additional, Brat, D., additional, Cho, U., additional, Hong, Y.-K., additional, Lober, R., additional, Lu, L., additional, Gephart, M. H., additional, Fisher, P., additional, Miyazaki, M., additional, Nishihara, H., additional, Itoh, T., additional, Kato, M., additional, Fujimoto, S., additional, Kimura, T., additional, Tanino, M., additional, Tanaka, S., additional, Nguyen, N., additional, Moes, G., additional, Villano, J. L., additional, Kanno, H., additional, Kato, Y., additional, Ohnishi, T., additional, Harada, H., additional, Ohue, S., additional, Kouno, S., additional, Inoue, A., additional, Yamashita, D., additional, Okamoto, S., additional, Nitta, M., additional, Muragaki, Y., additional, Maruyama, T., additional, Sawada, T., additional, Komori, T., additional, Saito, T., additional, Okada, Y., additional, Omay, S. B., additional, Gunel, J. M., additional, Clark, V. E., additional, Li, J., additional, Omay, E. Z. E., additional, Serin, A., additional, Kolb, L. E., additional, Hebert, R. M., additional, Bilguvar, K., additional, Ozduman, K., additional, Pamir, M. N., additional, Kilic, T., additional, Baehring, J., additional, Piepmeier, J. M., additional, Brennan, C. W., additional, Huse, J., additional, Gutin, P. H., additional, Yasuno, K., additional, Vortmeyer, A., additional, Gunel, M., additional, Pugh, S., additional, Rogers, C. L., additional, Brachman, D., additional, McMillan, W., additional, Jenrette, J., additional, Barani, I., additional, Shrieve, D., additional, Sloan, A., additional, Mehta, M., additional, Prabowo, A., additional, Iyer, A., additional, Veersema, T., additional, Anink, J., additional, Meeteren, A. S.-v., additional, Spliet, W., additional, van Rijen, P., additional, Ferrier, T., additional, Capper, D., additional, Thom, M., additional, Aronica, E., additional, Chharchhodawala, T., additional, Sable, M., additional, Sharma, M. C., additional, Sarkar, C., additional, Suri, V., additional, Singh, M., additional, Santosh, V., additional, Thota, B., additional, Srividya, M., additional, Sravani, K., additional, Shwetha, S., additional, Arivazhagan, A., additional, Thennarasu, K., additional, Hegde, A., additional, Kondaiah, P., additional, Somasundaram, K., additional, Rao, M., additional, Kumar, V. P., additional, Shastry, A., additional, Narayan, R., additional, Naz, S., additional, Venneti, S., additional, Garimella, M., additional, Sullivan, L., additional, Martinez, D., additional, Heguy, A., additional, Santi, M., additional, Thompson, C., additional, Judkins, A., additional, Voronovich, Z., additional, Chen, L., additional, Clark, K., additional, Walsh, M., additional, Mannas, J., additional, Horbinski, C., additional, Wiestler, B., additional, Holland-Letz, T., additional, Korshunov, A., additional, von Deimling, A., additional, Pfister, S. M., additional, Platten, M., additional, Weller, M., additional, Wick, W., additional, Zieman, G., additional, Dardis, C., additional, and Ashby, L., additional

Published
2013
Full Text
View/download PDF

21. -OMICS AND PROGNOSTIC MARKERS

Author

Moriera, F., primary, So, K., additional, Gould, P., additional, Kamnasaran, D., additional, Jensen, R. L., additional, Hussain, I., additional, Gutmann, D. H., additional, Gorovets, D., additional, Kastenhuber, E. R., additional, Pentsova, E., additional, Nayak, L., additional, Huse, J. T., additional, van den Bent, M. J., additional, Gravendeel, L. A., additional, Gorlia, T., additional, Kros, J. M., additional, Wesseling, P., additional, Teepen, J., additional, Idbaih, A., additional, Sanson, M., additional, Smitt, P. A. S., additional, French, P. J., additional, Zhang, W., additional, Zhang, J., additional, Hoadley, K., additional, Carter, B., additional, Li, S., additional, Kang, C., additional, You, Y., additional, Jiang, C., additional, Song, S., additional, Jiang, T., additional, Chen, C., additional, Grimm, C., additional, Weiler, M., additional, Claus, R., additional, Weichenhan, D., additional, Hartmann, C., additional, Plass, C., additional, Weller, M., additional, Wick, W., additional, Jenkins, R. B., additional, Sicotte, H., additional, Xiao, Y., additional, Fridley, B. L., additional, Decker, P. A., additional, Kosel, M. L., additional, Kollmeyer, T. M., additional, Fink, S. R., additional, Rynearson, A. L., additional, Rice, T., additional, McCoy, L. S., additional, Smirnov, I., additional, Tehan, T., additional, Hansen, H. M., additional, Patoka, J. S., additional, Prados, M. D., additional, Chang, S. M., additional, Berger, M. S., additional, Lachance, D. H., additional, Wiencke, J. K., additional, Wiemels, J. L., additional, Wrensch, M. R., additional, Gephart, M. H., additional, Lee, E., additional, Kyriazopoulou-Panagiotopoulou, S., additional, Milenkovic, L., additional, Xun, X., additional, Hou, Y., additional, Kui, W., additional, Edwards, M., additional, Batzoglou, S., additional, Jun, W., additional, Scott, M., additional, Hobbs, J. E., additional, Tipton, J., additional, Zhou, T., additional, Kelleher, N. L., additional, Chandler, J. P., additional, Schwarzenberg, J., additional, Czernin, J., additional, Cloughesy, T., additional, Ellingson, B., additional, Geist, C., additional, Phelps, M., additional, Chen, W., additional, Nakada, M., additional, Hayashi, Y., additional, Obuchi, W., additional, Ohtsuki, S., additional, Watanabe, T., additional, Ikeda, C., additional, Misaki, K., additional, Kita, D., additional, Uchiyama, N., additional, Terasaki, T., additional, Hamada, J.-i., additional, Hiddingh, L., additional, Tops, B., additional, Hulleman, E., additional, Kaspers, G.-J. L., additional, Vandertop, W. P., additional, Noske, D. P., additional, Wurdinger, T., additional, Jeuken, J. W., additional, See, A. P., additional, Hwang, T., additional, Shin, D., additional, Shin, J. H., additional, Gao, Y., additional, Lim, M., additional, Hutterer, M., additional, Michael, M., additional, Gerold, U., additional, Karin, S., additional, Ingrid, G., additional, Florian, D., additional, Armin, M., additional, Eugen, T., additional, Eberhard, G., additional, Gunther, S., additional, Cook, R. W., additional, Oelschlager, K., additional, Sevim, H., additional, Chung, L., additional, Wheeler, H. T., additional, Baxter, R. C., additional, McDonald, K. L., additional, Chaturbedi, A., additional, Yu, L., additional, Zhou, Y.-H., additional, Wong, A., additional, Fatuyi, R., additional, Linskey, M. E., additional, Lavon, I., additional, Shahar, T., additional, Zrihan, D., additional, Granit, A., additional, Ram, Z., additional, Siegal, T., additional, Brat, D. J., additional, Cooper, L. A., additional, Gutman, D. A., additional, Chisolm, C. S., additional, Appin, C., additional, Kong, J., additional, Kurc, T., additional, Van Meir, E. G., additional, Saltz, J. H., additional, Moreno, C. S., additional, Abuhusain, H. J., additional, Don, A. S., additional, Nagarajan, R. P., additional, Johnson, B. E., additional, Olshen, A. B., additional, Xie, M., additional, Wang, J., additional, Sundaram, V., additional, Paris, P., additional, Wang, T., additional, Costello, J. F., additional, Sijben, A. E., additional, Boots-Sprenger, S. H., additional, Boogaarts, J., additional, Rijntjes, J., additional, Geitenbeek, J. M., additional, van der Palen, J., additional, Bernsen, H. J., additional, Schnell, O., additional, Adam, S. A., additional, Eigenbrod, S., additional, Kretzschmar, H. A., additional, Tonn, J.-C., additional, Schuller, U., additional, Sperduto, P. W., additional, Kased, N., additional, Roberge, D., additional, Xu, Z., additional, Shanley, R., additional, Luo, X., additional, Sneed, P. K., additional, Chao, S. T., additional, Weil, R. J., additional, Suh, J., additional, Bhatt, A., additional, Jensen, A. W., additional, Brown, P. D., additional, Shih, H. A., additional, Kirkpatrick, J., additional, Gaspar, L. E., additional, Fiveash, J. B., additional, Chiang, V., additional, Knisely, J. P., additional, Sperduto, C. M., additional, Lin, N., additional, Mehta, M. P., additional, Kwatra, M. M., additional, Porter, T. M., additional, Brown, K. E., additional, Herndon, J. E., additional, Bigner, D. D., additional, Dahlrot, R. H., additional, Kristensen, B. W., additional, Hansen, S., additional, Sulman, E. P., additional, Cahill, D. P., additional, Wang, M., additional, Won, M., additional, Hegi, M. E., additional, Aldape, K. D., additional, Gilbert, M. R., additional, Sadr, E. S., additional, Tessier, A., additional, Sadr, M. S., additional, Alshami, J., additional, Sabau, C., additional, Del Maestro, R., additional, Neal, M. L., additional, Rockne, R., additional, Trister, A. D., additional, Swanson, K. R., additional, Maleki, S., additional, Back, M., additional, Buckland, M., additional, Brazier, D., additional, McDonald, K., additional, Cook, R., additional, Parker, N., additional, Wheeler, H., additional, Jalbert, L., additional, Elkhaled, A., additional, Phillips, J. J., additional, Yoshihara, H. A., additional, Parvataneni, R., additional, Srinivasan, R., additional, Bourne, G., additional, Cha, S., additional, Nelson, S. J., additional, Gilbert, M., additional, Cahill, D., additional, Hegi, M., additional, Colman, H., additional, Mehta, M., additional, Sulman, E., additional, Constantin, A., additional, Phillips, J., additional, Yoshihara, H., additional, Nelson, S., additional, Gunn, S., additional, Reveles, X. T., additional, Tirtorahardjo, B., additional, Strecker, M. N., additional, and Fichtel, L., additional

Published
2011
Full Text
View/download PDF

22. Orbital decompression in non-thyroid-associated diseases

Author

Ketharanathan, B., Andersen, M. S., Pedersen, C. B., Darling, P., Jakobseb, J., Bechtold, D., Molander, L. D., Gampenrieder, N., Dahlrot, R. H., Nguyen, N., Frantz Rom Poulsen, and Halle, B.

Subjects
musculoskeletal diseases, genetic structures, sense organs, eye diseases
Abstract

Orbital decompression is indicated in patients with lesions in relation to the orbit. Patients often present with proptosis, decreased visual acuity, impaired motility and inability to close the eye. The decompressive approach to the orbit is selected based on the location of the pathology. When considering medial orbital wall decompression, the endonasal endoscopic approach is minimally invasive with a low-risk profile. Moreover, it enables an optic canal decompression if needed. In this review, we present some approaches to orbital decompression together with two cases of endonasal endoscopic decompression.

23. Mixed effect model confirms increased risk of image changes with increasing linear energy transfer in proton therapy of gliomas.

Author

Vestergaard A, Kallehauge JF, Muhic A, Carlsen JF, Dahlrot RH, Lukacova S, Haslund CA, Lassen-Ramshad Y, Worawongsakul R, and Høyer M

Subjects
Humans, Male, Female, Middle Aged, Adult, Aged, Radiotherapy Dosage, Monte Carlo Method, Oligodendroglioma radiotherapy, Oligodendroglioma diagnostic imaging, Radiation Injuries etiology, Radiotherapy Planning, Computer-Assisted methods, Astrocytoma radiotherapy, Astrocytoma diagnostic imaging, Proton Therapy adverse effects, Proton Therapy methods, Brain Neoplasms radiotherapy, Brain Neoplasms diagnostic imaging, Magnetic Resonance Imaging, Linear Energy Transfer, Glioma radiotherapy, Glioma diagnostic imaging
Abstract

Background and Purpose: Radiation induced image changes (IC) on MRI have been observed after proton therapy for brain tumours. This study aims to create predictive models, with and without taking into account patient variation, based on dose, linear energy transfer (LET) and periventricular zone (PVZ) in a national cohort of patients with glioma treated with pencil beam scanning (PBS)., Materials and Methods: A cohort of 87 consecutive patients with oligodendroglioma or astrocytoma (WHO grade 2-4) treated with PBS from January 2019 to December 2021 was included. All patients were treated with three to four beams. Monte Carlo calculations of dose and LET were performed for all treatment plans. Lesion weighted as well as mixed effect logistic regression models were developed to predict IC in a voxel., Results: 12 patients (14 %) developed ICs on the follow-up MR-scans. Mixed effect modelling accounting for interpatient variation was justified by the non-negligible inter class correlation coefficient (ICC = 0.33). The two approaches identified similar model features and marginal improvement in model performance was found, when increasing model parameters from two (AUC = 0.92/0.94) to three (AUC = 0.93/0.95) parameters. Univariate analysis showed that patients treated with narrow beam configurations had an increased incidence of IC (p = 0.01)., Conclusion: 14% of patients developed IC following PT. Lesion-weighted and mixed effect models resulted in similar model performance confirming increased risk of IC with increasing LET. The beam arrangement seems to influence the risk of IC and needs further investigation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.)

Published
2025
Full Text
View/download PDF

24. Selection for proton radiotherapy of grade 1-3 glioma patients.

Author

Byskov CS, Muhic A, Dahlrot RH, Haslund CA, Guldberg TL, Høyer M, Nyström PW, Dysager L, Hansen S, Haldbo-Classen L, Trip AK, Lassen-Ramshad Y, Weber B, Lukacova S, Hansen CR, and Kallehauge JF

Abstract

Background: For adult patients with grade 1-3 gliomas, identifying patients with an indication for proton therapy (PT) can be challenging due to sparse evidence supporting its benefits. In this study, we aimed to ensure national consensus and develop a decision support tool to aid clinicians in identifying patients with grade 1-3 gliomas eligible for PT., Methods: Sixty-one historic patients referred for postoperative radiotherapy for glioma grade 1-3 were included in this study and had new photon therapy and PT plans calculated. These plans along with clinical parameters were presented to neurooncologists with experience in treating brain tumours. The patients were presented at three workshops (WSs), where each neurooncologist individually had to choose between photon and proton therapy. Important parameters were selected using cross validation. Multivariable logistic regression was used to predict the neurooncologists' treatment modality choice., Results: At the three WSs 23, 24 and 19 randomly selected patients were presented. Seventy-five percent of the neurooncologists agreed for 14 patients (61%), 16 patients (67%) and 15 patients (79%) at WS1, WS2 and WS3. Age at radiotherapy and difference in mean dose (ΔDmean) to the residual brain were significant predictors of the choice of treatment modality, p < 0.001. Model coefficients were: β age  = 0.07 per year (95% confidence interval [CI] = 0.05-0.09), and β Δdose  = -0.27 per Gy (95% CI=-0.36--0.18)., Conclusion: Higher degree of agreement was reached. Age and ΔDmean to the residual brain significantly predicted the choice of radiation modality. We have developed a decision support model which may aid in the selection of patients with glioma grade 1-3 to PT., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)

Published
2024
Full Text
View/download PDF

25. Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib.

Author

Mohammad H, Madsen K, Graumann O, Loya AC, Jensen NV, and Dahlrot RH

Abstract

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor., (© 2021 The Authors. Published by Elsevier Inc.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results